US-based diagnostics firm Alere’s subsidiary Standard Diagnostics in the Republic of Korea and global nonprofit organisation FIND have introduced a new rapid diagnostic test (RDT) for human African trypanosomiasis (HAT) or sleeping sickness.

The new SD BIOLINE HAT 2.0 is an immunochromatographic test designed to rapidly detect antibodies against the sleeping sickness-causing parasite, Trypanosoma brucei gambiense.

Discover B2B Marketing That Performs

Combine business intelligence and editorial excellence to reach engaged professionals across 36 leading media platforms.

Find out more

Health workers with minimal training can also perform the test by using fresh blood from a finger prick.

The test delivers results after only 15 minutes and does not require specialised equipment or electricity, enabling usage even in remote and resource-limited settings.

Research by the Universities of Dundee and Cambridge in the UK has contributed to the development of the test, which is intended to aid elimination of the disease in the communities of sub-Saharan African countries.

"The test delivers results after only 15 minutes and does not require specialised equipment or electricity."

The test includes two recombinant parasite antigens that were jointly developed by the universities.

GlobalData Strategic Intelligence

US Tariffs are shifting - will you react or anticipate?

Don’t let policy changes catch you off guard. Stay proactive with real-time data and expert analysis.

By GlobalData

FIND CEO Dr Catharina Boehme said: “FIND’s role in supporting the development of the new HAT screening test has included the selection of candidate antigens, collection of clinical samples, and conducting clinical trials.

“Today, we are thrilled to announce the launch of this new test, which will facilitate diagnosis of sleeping sickness patients in even the most remote corners of affected countries, and enhance the prospects of achieving and sustaining elimination of the disease.”

FIND and Standard Diagnostics have previously partnered to develop another rapid HAT diagnostic test, SD BIOLINE HAT, which is currently available in approximately 17 endemic countries.


Image: SD BIOLINE HAT 2.0 kit. Photo: courtesy of the University of Dundee.

Medical Device Network Excellence Awards - Nominations Closed

Nominations are now closed for the Medical Device Network Excellence Awards. A big thanks to all the organisations that entered – your response has been outstanding, showcasing exceptional innovation, leadership, and impact

Excellence in Action
Awarded for Innovation in Remote Hearing Diagnostics , hearX’s Self Test Kit (STK) delivers clinically validated audiometry via smart devices, enabling remote, scalable hearing assessments in homes, clinics and retail. Learn how hearX is redefining hearing care delivery and reducing costs for providers globally.

Discover the Impact